Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Vulnerability to omega-3 deprivation in a mouse model of NMDA receptor hypofunction.

Islam R, Trépanier MO, Milenkovic M, Horsfall W, Salahpour A, Bazinet RP, Ramsey AJ.

NPJ Schizophr. 2017 Mar 22;3:12. doi: 10.1038/s41537-017-0014-8. eCollection 2017.

2.

Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?

Joseph J, Depp C, Shih PB, Cadenhead KS, Schmid-Schönbein G.

Front Neurosci. 2017 Mar 27;11:155. doi: 10.3389/fnins.2017.00155. eCollection 2017.

3.

N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology.

Pusceddu MM, Kelly P, Stanton C, Cryan JF, Dinan TG.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw078. doi: 10.1093/ijnp/pyw078. Print 2016 Dec. Review.

4.

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.

Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M.

Mediators Inflamm. 2016;2016:3476240. doi: 10.1155/2016/3476240. Epub 2016 Jul 25. Review.

5.

Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data.

Bozzatello P, Brignolo E, De Grandi E, Bellino S.

J Clin Med. 2016 Jul 27;5(8). pii: E67. doi: 10.3390/jcm5080067. Review.

6.

Diffusion Imaging of White Matter In Schizophrenia: Progress and Future Directions.

Karlsgodt KH.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 May;1(3):209-217.

7.

Effects of Omega-3 Supplement in the Treatment of Patients with Bipolar I Disorder.

Shakeri J, Khanegi M, Golshani S, Farnia V, Tatari F, Alikhani M, Nooripour R, Ghezelbash MS.

Int J Prev Med. 2016 May 19;7:77. doi: 10.4103/2008-7802.182734. eCollection 2016.

8.

Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?

Knöchel C, Voss M, Grüter F, Alves GS, Matura S, Sepanski B, Stäblein M, Wenzler S, Prvulovic D, Carvalho AF, Oertel-Knöchel V.

Curr Neuropharmacol. 2015;13(5):663-80. Review.

9.

Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.

Pawełczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gębski P, Szemraj J, Żurner N, Pawełczyk A.

BMC Psychiatry. 2015 May 2;15:97. doi: 10.1186/s12888-015-0473-2.

10.

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K.

Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):62-7. doi: 10.9758/cpn.2015.13.1.62.

11.

Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia.

Jamilian H, Solhi H, Jamilian M.

Glob J Health Sci. 2014 Sep 18;6(7 Spec No):103-8. doi: 10.5539/gjhs.v6n7p103.

12.

A mathematical model of dysfunction of the thalamo-cortical loop in schizophrenia.

Rosjat N, Popovych S, Daun-Gruhn S.

Theor Biol Med Model. 2014 Oct 18;11:45. doi: 10.1186/1742-4682-11-45.

13.

Mass spectrometric analysis of oxidized eicosapentaenoic Acid sodium salt.

Jordan KD, Upmacis RK.

Lipid Insights. 2013 May 6;6:21-35. doi: 10.4137/LPI.S10862. eCollection 2013.

14.

Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies.

Shimamoto C, Ohnishi T, Maekawa M, Watanabe A, Ohba H, Arai R, Iwayama Y, Hisano Y, Toyota T, Toyoshima M, Suzuki K, Shirayama Y, Nakamura K, Mori N, Owada Y, Kobayashi T, Yoshikawa T.

Hum Mol Genet. 2014 Dec 15;23(24):6495-511. doi: 10.1093/hmg/ddu369. Epub 2014 Jul 15. Erratum in: Hum Mol Genet. 2015 Apr 15;24(8):2409.

15.

Impact of lipid nutrition on neural stem/progenitor cells.

Sakayori N, Kimura R, Osumi N.

Stem Cells Int. 2013;2013:973508. doi: 10.1155/2013/973508. Epub 2013 Oct 23. Review.

16.

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.

Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS.

Schizophr Bull. 2014 Jan;40(1):181-91. doi: 10.1093/schbul/sbt139. Epub 2013 Oct 8.

17.

The effects of omega 3 fatty acid supplementation on brain tissue oxidative status in aged wistar rats.

Avramovic N, Dragutinovic V, Krstic D, Colovic M, Trbovic A, de Luka S, Milovanovic I, Popovic T.

Hippokratia. 2012 Jul;16(3):241-5.

18.

Role of Long-Chain Omega-3 Fatty Acids in Psychiatric Practice.

McNamara RK, Strawn JR.

PharmaNutrition. 2013 Apr;1(2):41-49.

19.

A review of anti-inflammatory agents for symptoms of schizophrenia.

Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL.

J Psychopharmacol. 2013 Apr;27(4):337-42. doi: 10.1177/0269881112467089. Epub 2012 Nov 13. Review.

20.

(N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders.

Prior PL, Galduróz JC.

Adv Nutr. 2012 May 1;3(3):257-65. doi: 10.3945/an.111.001693. Review.

Supplemental Content

Support Center